Citation Impact
Citing Papers
Targeting a host-cell entry factor barricades antiviral-resistant HCV variants from on-therapy breakthrough in human-liver mice
2015
Intracellular Innate Immune Cascades and Interferon Defenses That Control Hepatitis C Virus
2009
Hepatitis C virus drug resistance–associated substitutions: State of the art summary
2015
Treatment failure in hepatitis C: Mechanisms of non-response
2008
Combined X-ray, NMR, and Kinetic Analyses Reveal Uncommon Binding Characteristics of the Hepatitis C Virus NS3-NS4A Protease Inhibitor BI 201335
2011
Hepatitis C Virus Non-structural Protein 3 (HCV NS3): A Multifunctional Antiviral Target
2010
The Spring α-Helix Coordinates Multiple Modes of HCV (Hepatitis C Virus) NS3 Helicase Action
2016 StandoutNobel
Phage-assisted evolution of an adenine base editor with improved Cas domain compatibility and activity
2020 StandoutNobel
SEC14L2 enables pan-genotype HCV replication in cell culture
2015 StandoutNatureNobel
Naturally occurring mutations associated with resistance to HCV NS5B polymerase and NS3 protease inhibitors in treatment-naïve patients with chronic hepatitis C
2015
Development of novel therapies for hepatitis C
2010
Induction and Evasion of Innate Antiviral Responses by Hepatitis C Virus
2010
HCV genotype 1-6 NS3 residue 80 substitutions impact protease inhibitor activity and promote viral escape
2018
Hepatitis C virus resistance to protease inhibitors
2011
Recapitulation of the hepatitis C virus life-cycle in engineered murine cell lines
2013 StandoutNobel
Viral genome imaging of hepatitis C virus to probe heterogeneous viral infection and responses to antiviral therapies
2016 StandoutNobel
Longitudinal transcriptomic characterization of the immune response to acute hepatitis C virus infection in patients with spontaneous viral clearance
2018 StandoutNobel
Signal integration by JNK and p38 MAPK pathways in cancer development
2009 Standout
MC4R Agonists: Structural Overview on Antiobesity Therapeutics
2018 StandoutNobel
NS5A Promotes Constitutive Degradation of IP3R3 to Counteract Apoptosis Induced by Hepatitis C Virus
2018 StandoutNobel
Multi-input chemical control of protein dimerization for programming graded cellular responses
2019 StandoutNobel
The importance of resistance to direct antiviral drugs in HCV infection in clinical practice
2015
Prospects for prophylactic and therapeutic vaccines against the hepatitis C viruses
2010 StandoutNobel
Unconventional miR-122 binding stabilizes the HCV genome by forming a trimolecular RNA structure
2013 StandoutNobel
Modelling hepatitis C therapy—predicting effects of treatment
2015
Whole Genome Pyrosequencing of Rare Hepatitis C Virus Genotypes Enhances Subtype Classification and Identification of Naturally Occurring Drug Resistance Variants
2012
Toll-like Receptors and Their Crosstalk with Other Innate Receptors in Infection and Immunity
2011 Standout
Lethal Mutagenesis of Hepatitis C Virus Induced by Favipiravir
2016 StandoutNobel
New horizons in hepatitis C antiviral therapy with direct-acting antivirals
2013
The Molecular Basis of Drug Resistance against Hepatitis C Virus NS3/4A Protease Inhibitors
2012
A central hydrophobic E1 region controls the pH range of hepatitis C virus membrane fusion and susceptibility to fusion inhibitors
2019 StandoutNobel
The role of resistance in HCV treatment
2012
Hepatitis C: viral and host factors associated with non-response to pegylated interferon plus ribavirin
2010
Constraining Cyclic Peptides To Mimic Protein Structure Motifs
2014
Next generation sequencing of the hepatitis C virus NS5B gene reveals potential novel S282 drug resistance mutations
2015
Resistance to nucleotide analogue inhibitors of hepatitis C virus NS5B: mechanisms and clinical relevance
2014
Inhibitors of c-Jun N-terminal kinases—JuNK no more?
2007
Rapid emergence of telaprevir resistant hepatitis C virus strain from wildtype clone in vivo
2011
Expanded classification of hepatitis C virus into 7 genotypes and 67 subtypes: Updated criteria and genotype assignment web resource
2013 StandoutNobel
The ins and outs of hepatitis C virus entry and assembly
2013 StandoutNobel
SwissParam: A fast force field generation tool for small organic molecules
2011 Standout
Hepatitis C Virus (HCV) Genotype 1 Subtype Identification in New HCV Drug Development and Future Clinical Practice
2009
The use of spirocyclic scaffolds in drug discovery
2014 Standout
Hepatitis C Virus-Specific Directly Acting Antiviral Drugs
2013
Antiviral therapy of hepatitis C in 2014: Do we need resistance testing?
2014
Short-Range Exosomal Transfer of Viral RNA from Infected Cells to Plasmacytoid Dendritic Cells Triggers Innate Immunity
2012
Expression of heterologous proteins flanked by NS3-4A cleavage sites within the hepatitis C virus polyprotein
2013 StandoutNobel
Discovery of a Non-Peptidic Inhibitor of West Nile Virus NS3 Protease by High-Throughput Docking
2009
The HCV Life Cycle: In vitro Tissue Culture Systems and Therapeutic Targets
2014 Standout
Understanding the hepatitis C virus life cycle paves the way for highly effective therapies
2013 StandoutNobel
Genome-wide RNAi Screen Reveals a New Role of a WNT/CTNNB1 Signaling Pathway as Negative Regulator of Virus-induced Innate Immune Responses
2013
Cleavage of mitochondrial antiviral signaling protein in the liver of patients with chronic hepatitis C correlates with a reduced activation of the endogenous interferon system†
2009
Development of a high-throughput pyrosequencing assay for monitoring temporal evolution and resistance associated variant emergence in the Hepatitis C virus protease coding-region
2014
A system for the continuous directed evolution of proteases rapidly reveals drug-resistance mutations
2014
Innate Immune Responses to Hepatitis C Virus
2013 StandoutNobel
Current race in the development of DAAs (direct-acting antivirals) against HCV
2014
Genotype and Subtype Profiling of PSI-7977 as a Nucleotide Inhibitor of Hepatitis C Virus
2012
Characterization of Novel Splice Variants of Zinc Finger Antiviral Protein (ZAP)
2019 StandoutNobel
Data-Mining for Sulfur and Fluorine: An Evaluation of Pharmaceuticals To Reveal Opportunities for Drug Design and Discovery
2013 Standout
Molecular Mechanisms of Viral and Host Cell Substrate Recognition by Hepatitis C Virus NS3/4A Protease
2011
Fluorine and Fluorinated Motifs in the Design and Application of Bioisosteres for Drug Design
2018 Standout
A Survey of the Role of Noncovalent Sulfur Interactions in Drug Design
2015
Hepatitis C virus infects rhesus macaque hepatocytes and simianized mice
2015 StandoutNobel
Enhancement of the Replication of Hepatitis C Virus Replicons of Genotypes 1 to 4 by Manipulation of CpG and UpA Dinucleotide Frequencies and Use of Cell Lines Expressing SECL14L2 for Antiviral Resistance Testing
2016
Ultrastructural analysis of hepatitis C virus particles
2013 StandoutNobel
Next Generation of Fluorine-Containing Pharmaceuticals, Compounds Currently in Phase II–III Clinical Trials of Major Pharmaceutical Companies: New Structural Trends and Therapeutic Areas
2016 Standout
Structural Analysis of Asunaprevir Resistance in HCV NS3/4A Protease
2014
Efficient Replication of Genotype 3a and 4a Hepatitis C Virus Replicons in Human Hepatoma Cells
2012 StandoutNobel
Discovery and Development of Simeprevir (TMC435), a HCV NS3/4A Protease Inhibitor
2014
The Origin of Chalcogen-Bonding Interactions
2017 Standout
Stereoselective Enzymatic Synthesis of Heteroatom-Substituted Cyclopropanes
2018 StandoutNobel
Palladium-Catalyzed Transformations of Alkyl C–H Bonds
2016 Standout
Virologic Tools for HCV Drug Resistance Testing
2015
GS‐9857 in patients with chronic hepatitis C virus genotype 1–4 infection: a randomized, double‐blind, dose‐ranging phase 1 study
2016
Macrocycles: lessons from the distant past, recent developments, and future directions
2014
De novo design of covalently constrained mesosize protein scaffolds with unique tertiary structures
2017 StandoutNobel
Enantioselective palladium(0)-catalyzed intramolecular cyclopropane functionalization: access to dihydroquinolones, dihydroisoquinolones and the BMS-791325 ring system
2015
Fast Hepatitis C Virus RNA Elimination and NS5A Redistribution by NS5A Inhibitors Studied by a Multiplex Assay Approach
2015 StandoutNobel
Response of Hepatitis C Virus to Long-Term Passage in the Presence of Alpha Interferon: Multiple Mutations and a Common Phenotype
2013 StandoutNobel
Drug resistance against HCV NS3/4A inhibitors is defined by the balance of substrate recognition versus inhibitor binding
2010
EASL Recommendations on Treatment of Hepatitis C 2018
2018 Standout
Expanding the Host Range of Hepatitis C Virus through Viral Adaptation
2016 StandoutNobel
Increased Replicative Fitness Can Lead to Decreased Drug Sensitivity of Hepatitis C Virus
2014 StandoutNobel
Viral persistence, liver disease, and host response in a hepatitis C–like virus rat model
2017 StandoutNobel
Replicons of a Rodent Hepatitis C Model Virus Permit Selection of Highly Permissive Cells
2019 StandoutNobel
Deep Sequencing and Phylogenetic Analysis of Variants Resistant to Interferon-Based Protease Inhibitor Therapy in Chronic Hepatitis Induced by Genotype 1b Hepatitis C Virus
2015
Biogenesis, Secretion, and Intercellular Interactions of Exosomes and Other Extracellular Vesicles
2014 Standout
Macrocyclic Drugs and Clinical Candidates: What Can Medicinal Chemists Learn from Their Properties?
2013
Viral Quasispecies Evolution
2012
Internal Disequilibria and Phenotypic Diversification during Replication of Hepatitis C Virus in a Noncoevolving Cellular Environment
2017 StandoutNobel
Hepatitis C Virus Genotype 5a Subgenomic Replicons for Evaluation of Direct-Acting Antiviral Agents
2014 StandoutNobel
Stapled β-Hairpins Featuring 4-Mercaptoproline
2021 StandoutNobel
Single‐molecule imaging reveals the translocation and DNA looping dynamics of hepatitis C virus NS3 helicase
2017 StandoutNobel
Principles and Applications of Halogen Bonding in Medicinal Chemistry and Chemical Biology
2012 Standout
Novel Therapies for Hepatitis C: Insights from the Structure of the Virus
2011
Barrier-Independent, Fitness-Associated Differences in Sofosbuvir Efficacy against Hepatitis C Virus
2016 StandoutNobel
Importance of HCV genotype 1 subtypes for drug resistance and response to therapy
2014
Works of Tse‐I Lin being referenced
Discovery of novel potent and selective dipeptide hepatitis C virus NS3/4A serine protease inhibitors
2008
Antiviral Suppression vs Restoration of RIG-I Signaling by Hepatitis C Protease and Polymerase Inhibitors
2008
Evaluation of the anti-hepatitis C virus effect of novel potent, selective, and orally bioavailable JNK and VEGFR kinase inhibitors
2007
Induced‐Fit Binding of the Macrocyclic Noncovalent Inhibitor TMC435 to its HCV NS3/NS4A Protease Target
2010
Tracking the Evolution of MultipleIn VitroHepatitis C Virus Replicon Variants under Protease Inhibitor Selection Pressure by 454 Deep Sequencing
2010
Antiviral Activity and Mode of Action of TMC647078, a Novel Nucleoside Inhibitor of the Hepatitis C Virus NS5B Polymerase
2011
Nucleotide Prodrugs of 2′-Deoxy-2′-spirooxetane Ribonucleosides as Novel Inhibitors of the HCV NS5B Polymerase
2013
In Vitro Resistance Profile of the Hepatitis C Virus NS3/4A Protease Inhibitor TMC435
2010
In Vitro Activity and Preclinical Profile of TMC435350, a Potent Hepatitis C Virus Protease Inhibitor
2009